Welwyn, United Kingdom

Doug Easton

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 19(Granted Patents)


Location History:

  • Welwyn, GB (2015 - 2017)
  • Herts, GB (2019)

Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Doug Easton: Innovator in Breast Cancer Research

Introduction

Doug Easton is a prominent inventor based in Welwyn, GB. He has made significant contributions to the field of breast cancer research, holding a total of 4 patents. His work focuses on the diagnosis, prognosis, and treatment of breast cancer, providing valuable insights and tools for medical professionals.

Latest Patents

Easton's latest patents include innovative markers for breast cancer. These patents detail correlations between polymorphisms and breast cancer, offering methods for diagnosing, prognosing, and treating the disease. Additionally, he has developed systems and kits designed for the diagnosis, prognosis, and treatment of breast cancer. His work also encompasses methods for identifying breast cancer modulators, further advancing the understanding of this critical health issue.

Career Highlights

Doug Easton is associated with Cambridge Enterprise Limited, where he continues to push the boundaries of breast cancer research. His dedication to innovation in this field has positioned him as a key figure in the medical community.

Collaborations

Easton has collaborated with notable colleagues, including David R Cox and Dennis G Ballinger. These partnerships have enhanced his research efforts and contributed to the development of groundbreaking solutions in breast cancer treatment.

Conclusion

Doug Easton's work exemplifies the impact of innovation in medical research, particularly in the fight against breast cancer. His patents and collaborations reflect a commitment to improving diagnosis and treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…